Indications and Uses
Anaflex® is indicated for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis,
juvenile rheumatoid arthritis, acute gout and acute musculoskeletal disorder (such as sprains and
strains, direct trauma, lumbosacral pain, cervical spondylitis, tenosynovitis and fibrositis), migraine,
post-operative pain and dysmenorrhoea.
Dosage and Administration
For rheumatoid arthritis, osteoarthritis, ankylosing spondylitis:
The usual dose of Anaflex® is 500 mg to 1 g per day taken in two divided doses at 12-hour intervals
or as a single administration of Anaflex® 500 mg or Anaflex® SR 500 mg once daily (morning or
evening) after meals.
For acute gout:
The initial dose of Anaflex® is 750 mg, and then 250mg every eight hours until the attack subsides.
For analgesia and acute musculoskeletal disorders:
The initial dose of Anaflex® is 500 mg, and then 250 mg at 6-8 hour intervals as needed with a
maximum 1250 mg daily.
The usual dose of Anaflex® is 500 mg should be given initially, followed by 250mg at 6-8 hour
intervals for up to 5 days.
The usual dose of Anaflex® is 500 mg should be given initially, then 500mg at least 30 minutes after
the initial dose.
Children over 5 years:
In juvenile arthritis (children over 5 years):
The usual dosage of Anaflex® is 10 mg/kg/day taken in two doses at 12-hour intervals is
Anaflex® Gel is to be applied 2-6 times a day as required and is not recommended for use in
Use in pregnancy & lactation
The safety of naproxen administration during pregnancy and for use in nursing mother has not been
established. Therefore, the possible hazards should be weighed against the potential benefits.
Gastro-intestinal: Nausea, vomiting, pain, occasionally bleeding and ulceration and colitis.
Only for the use of Medical Professionals
Dermatological: Skin rashes, urticaria, angio-oedema; rarely anaphylactic reactions and eosinophilic
Haematological: Thrombocytopenia, granulocytopenia, including agranulocytosis, aplastic anaemia.
Other: Tinnitus, hearing impairment, vertigo, mild peripheral oedema (patients with compromised
cardiac function may be at a higher risk on naproxen), rarely jaundice, fatal hepatitis, nephropathy,
haematuria, visual disturbances, vasuculitis, aseptic meningitis and ulcerative stomatitis.
Naproxen is contraindicated in patients’ active peptic ulceration, hypersensitivity to naproxen or
naproxen sodium formulations, aspirin/other NSAIDs.
Naproxen should be used with care in patients with a history of GI disease, asthma, or allergic
disease, impaired renal and hepatic function. Naproxen decreases platelet aggregation and prolongs
Overdosage with naproxen may be characterized by drowsiness, heartburn, indigestion, nausea and
vomiting. No evidences of toxicity or late sequelae have been reported 5-15 months after ingestion,
for three to seven days, of doses up to 3g/day.
Caution is required if any of the following is administered concurrently with naproxen: hydantoins,
anticoagulants or highly protein-bound sulphonamides, furesamide, propranolol or other betablockers,
lithium, probenecid, methotrexate.